Table 5. Comparison of primary and key secondary outcomes during the post intervention period rainy season between study groups.

Outcomes	Placebo¶	SP bimonthly¶					AS+AQ bimonthly¶				AS+AQ monthly¶
	Episodes	Rate*	Episodes	Rate*	PE (95% CI)	p-value	Episodes	Rate*	PE (95% CI)	p-value	Episodes	Rate*	PE (95% CI)	p-value
Total OPD attendance	96	632.5	88	557.2	11.9 (−31.2 to −26.7)	0.895	68	473.7	6.1 (−28.6 to 31.4)	0.696	101	596.26	−6.8 (−41.7 to 19.4)	0.646
Malaria with any parasitaemia	46	15.2	59	21.1	−38.8 (−108.6 to 5.6)	0.094	41	16.0	−5.3 (−65.3 to 30.0)	0.740	60	21.0	−38.2 (−115.8 to 1.4)	0.059)
Malaria with high density (>7000 parasites /µl)	29	9.8	36	12.9	−28.7 (−112.9 to 22.2)	0.326	28	10.9	−11.2 (−88.4 to 34.4)	0.693	40	14.0	−42.9 (−145.4 to 7.0)	0.095
Anaemia (Hb<8.0 g/dl)	25	42.3	25	37.6	7.3 (−71.0 to 49.8)	0.193	13	31.0	21.7 (−61.6 to 62.0)	0.491	20	32.7	21.0 (−51.1 to 58.7)	0.523
Malaria anaemia	14	4.7	21	7.5	−51.9 (−204.0 to 24.1)	0.238	11	4.3	8.5 (−88.3 to 61.9)	0.684	16	5.6	−19.1 (−156.5 to 39.9)	0.559
All cause admissions	11	3.2	14	3.9	−21.9 (−592 to 83.6)	0.950	10	3.0	6.3 (−567.6 to 79.9)	0.871	10	2.7	15.6 (−391.1 to 78.0)	0.962
Malaria admissions	7	2.0	9	2.5	−6.2 (−463.8 to 79.9)	0.943	6	1.8	10.0 (−783.4 to 84.9)	0.888	6	1.6	20.0 (−542.9 to 83.2)	0.968

^*PE: protective efficacy = (1−rate ratio)^*100; rate ratio was ^¶adjusted for age at enrolment and bednet use